Evidence map›Paper›PMID 34638626›Full record

ArticleInternational journal of molecular sciences2021

Cilostazol Induces eNOS and TM Expression via Activation with Sirtuin 1/Krüppel-like Factor 2 Pathway in Endothelial Cells.

Chih-Hsien Wu, Yi-Lin Chiu, Chung-Yueh Hsieh, Guo-Shiang Tsung, Lian-Shan Wu, Cheng-Chung Cheng, Tsung-Neng Tsai

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. SIRT1 and thrombosis.Frontiers in molecular biosciences · 2023
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Chih-Hsien WuNational Defense Medical Center, Department of Biochemistry, Taipei 114201, Taiwan.
Yi-Lin ChiuNational Defense Medical Center, Department of Biochemistry, Taipei 114201, Taiwan.ORCID 0000-0002-1827-6924
Chung-Yueh HsiehDepartment of Internal Medicine, Division of Cardiology, Taoyuan Armed Forces General Hospital, Taoyuan City 325208, Taiwan.
Guo-Shiang TsungDepartment of Internal Medicine, Division of Cardiology, Taoyuan Armed Forces General Hospital, Taoyuan City 325208, Taiwan.
Lian-Shan WuDepartment of Internal Medicine, Division of Cardiology, Hualien Armed Forces General Hospital, Hualien County 325208, Taiwan.
Cheng-Chung ChengDepartment of Internal Medicine, Division of Cardiology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114202, Taiwan.
Tsung-Neng TsaiDepartment of Internal Medicine, Division of Cardiology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114202, Taiwan.
Tri-Service General Hospital · TWTaoyuan Armed Forces General Hospital · TWHualien Armed Forces General Hospital · TWNational Defense Medical Center · TW

Funding

Hualien Armed Forces General Hospital 805-C108-16, HAFGH-D-109004Hualien Armed Forces General Hospital HAFGH-D-110005Ministry of National Defense-Medical Affairs Bureau MAB-109-004Ministry of Science and Technology, Taiwan MOST 108-2314-B-016-046 -Ministry of Science and Technology, Taiwan MOST 109-2314-B-016 -043 -MY2Tri-Service General Hospital TSGHC106-005-007-S04Tri-Service General Hospital TSGH-C107-005-005-007-S04
6 · The paper itself

Abstract

Cilostazol was suggested to be beneficial to retard in-stent atherosclerosis and prevent stent thrombosis. However, the mechanisms responsible for the beneficial effects of cilostazol are not fully understood. In this study, we attempted to verify the mechanism of the antithrombotic effect of cilostazol. Human umbilical vein endothelial cells (HUVECs) were cultured with various concentrations of cilostazol to verify its impact on endothelial cells. KLF2, silent information regulator transcript-1 (SIRT1), endothelial nitric oxide synthase (eNOS), and endothelial thrombomodulin (TM) expression levels were examined. We found cilostazol significantly activated KLF2 expression and KLF2-related endothelial function, including eNOS activation, Nitric oxide (NO) production, and TM secretion. The activation was regulated by SIRT1, which was also stimulated by cilostazol. These findings suggest that cilostazol may be capable of an antithrombotic and vasculoprotective effect in endothelial cells.

Indexed as

Cells, CulturedCilostazolHumansHuman Umbilical Vein Endothelial CellsKruppel-Like Transcription FactorsNitric OxideNitric Oxide Synthase Type IIISirtuin 1ThrombomodulinCilostazolKLF2 protein, humanKruppel-Like Transcription FactorsNitric OxideNitric Oxide Synthase Type IIINOS3 protein, humanSIRT1 protein, humanSirtuin 1THBD protein, humanThrombomodulincilostazolendothelial cellsendothelial nitric oxide synthaseKrüppel-like factor 2nitric oxidethrombomodulin

Identifiers

PMID34638626
PMCPMC8508979
OpenAlexW3203845560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.